Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 8 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Astellas Pharma Inc. has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 7 examiners across 7 art units, creating a fully distributed examination profile across the active portfolio.
ELENISTE, PIERRE PAUL is the busiest examiner, with 1 pending matter. Each examiner carries one listed matter, so counsel should rely on disciplined portfolio coordination while developing responses tailored to each technical and examination setting.
The seven-art-unit distribution makes a single standardized prosecution response unsuitable as a complete strategy. A central review can identify recurring claim, disclosure, or prior-art themes, but each record should retain its own examiner-specific analysis and amendment rationale.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §103 only | 2 (25%) |
| §112 only | 1 (12%) |
| Double-patenting + other | 3 (38%) |
| Multi-statute (no §101) | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ELENISTE, PIERRE PAUL | 1 | 35.4% | +31.1% |
| WHITEMAN, BRIAN A | 1 | 68.4% | +16.8% |
| BAUER, BRIANNA LEE | 1 | 66.7% | +0.0% |
| FORRISTALL, JOSHUA L | 1 | 65.8% | +15.3% |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.1% |
| CHEONG, CHEOM-GIL | 1 | 64.1% | +53.1% |
| OH, TAYLOR V | 1 | 81.3% | +15.3% |
| NATARAJAN, MEERA | 1 | 62.6% | +17.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279103 | Methods of Reducing Risk of Prostate Cancer Progression | OH, TAYLOR V | 17d overdue |
| 18269531 | GUIDE RNA FOR EDITING POLYADENYLATION SIGNAL SEQUENCE OF TARGET RNA | WHITEMAN, BRIAN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17632157 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF CANCER | NATARAJAN, MEERA | 31d overdue |
| 18279103 | Methods of Reducing Risk of Prostate Cancer Progression | OH, TAYLOR V | 17d overdue |
| 18563354 | MACHINE LEARNING METHODS TO PREDICT MENOPAUSE SYMPTOMS AND TREATMENT OPTIONS | FORRISTALL, JOSHUA L | 5d overdue |
| 18845652 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ELENISTE, PIERRE PAUL | — |
| 18269531 | GUIDE RNA FOR EDITING POLYADENYLATION SIGNAL SEQUENCE OF TARGET RNA | WHITEMAN, BRIAN A | — |
| 18552113 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | SKELDING, ZACHARY S | — |
| 18468103 | BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN6 OR CLAUDIN18.2 AND CD3 FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | CHEONG, CHEOM-GIL | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1636 | 1 |
| 1623 | 1 |
| 2857 | 1 |
| 1644 | 1 |
| 1645 | 1 |
| 1625 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18845652 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ELENISTE, PIERRE PAUL | 1622 | §112 | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18269531 | GUIDE RNA FOR EDITING POLYADENYLATION SIGNAL SEQUENCE OF TARGET RNA | WHITEMAN, BRIAN A | 1636 | §101§102§103§112DP | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18566516 | METHODS OF USE OF PPAR AGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | BAUER, BRIANNA LEE | 1623 | §103§112DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18563354 | MACHINE LEARNING METHODS TO PREDICT MENOPAUSE SYMPTOMS AND TREATMENT OPTIONS | FORRISTALL, JOSHUA L | 2857 | §103 | Final Rejection | 5d overdue | Pending | Nov 21, 2023 |
| 18552113 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | SKELDING, ZACHARY S | 1644 | §102§112DP | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18468103 | BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN6 OR CLAUDIN18.2 AND CD3 FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | CHEONG, CHEOM-GIL | 1645 | §103DP | Final Rejection | — | Pending | Sep 15, 2023 |
| 18279103 | Methods of Reducing Risk of Prostate Cancer Progression | OH, TAYLOR V | 1625 | §102§103§112 | Final Rejection | 17d overdue | Pending | Aug 28, 2023 |
| 17632157 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF CANCER | NATARAJAN, MEERA | 1643 | §103 | Non-Final OA | 31d overdue | Pending | Feb 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAstellas Pharma Inc. has 8 pending office actions as of October 2026, spread across 8 art units and 8 examiners.
Pierre Paul Eleniste has the most, with 1 of Astellas Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
